[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579745":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":10,"responsibleParty":36,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rivastigmine Mini-Tablet",null,"Start with a dose of 1.5 mg twice daily (bid), titrate every two weeks, and the maximum dose should not exceed 12 mg.",[13],"Drug: Rivastigmine Mini-Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"Donepezil Hydrochloride","Start with 5mg taken once daily before bedtime. If the patient tolerates the initial dose well, it will be increased to 10 mg per day after four weeks.",[18],"Drug: Donepezil Hydrochloride",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Treatment group: Rivastigmine Mini-Tablet",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":10},"Control group: Donepezil Hydrochloride",[15],[28],{"name":29,"affiliation":5,"role":30},"Yongan Sun, Phd","PRINCIPAL_INVESTIGATOR",[32],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","83572462","sya@bjmu.edu.cn",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100579745","rivastigmine-mini-tablet-for-alzheimers-disease-100579745",false,"NCT06828289","Rivastigmine Mini-Tablet for Alzheimer's Disease","Observational Study of Rivastigmine Mini-Tablet in Patients with Alzheimer's Disease","Inclusion Criteria:\n\n* Age 50 or older\n* Meet the National Institute of Aging-Alzheimer's Association clinical criteria for probable Alzheimer's disease\n* Have a Mini-Mental State Examination score of 10 to 24 at Screening and Baseline\n* Geriatric Depression Scale score \\\u003C=7 at Screening\n* Hachinski Ischemic Scale \\\u003C=4 at Screening\n* Brain MRI should meet: no infarcts in key areas (thalamus, hippocampus, entorhinal cortex, perirhinal cortex, angular gyrus, etc.), ≤ 2 stroke lesions \\> 1.5 cm in diameter, and Fazekas Scale - assessed white matter lesion grade\n\n  * 2\\.\n* Patients whose caregivers are well-informed about the patients' condition and, if possible, live with them.\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Any systemic or neurological condition that could contribute to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease\n* Any psychiatric diagnosis or symptoms (hallucinations, major depression, delusions, etc) interfering with study procedures\n* An advanced, severe or unstable disease of any type (cardiac, respiratory, gastrointestinal, renal disease, etc) that may interfere with efficacy evaluations\n* Subjects treated with medication for dementia two weeks prior to baseline","ALL","50 Years",{"count":48,"type":49},1000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).",[53],"Alzheimer's Disease","NOT_YET_RECRUITING","2025-02-18",{"date":57,"type":58},"2025-02-20","ACTUAL",{"date":60,"type":49},"2025-02-28",{"date":62,"type":49},"2026-12-31",{"name":5,"class":6}]